<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    T2 Biosystems, Inc.

    T2 Biosystems, Inc.

    T2 Biosystems, a leader in the development and commercialization of innovative med...

    T2 Biosystems, a leader in the development and ...

    Filing Type:    PU
    Intercept Pharmaceuticals, Inc.

    Intercept Pharmaceuticals, Inc.

    Intercept is a biopharmaceutical company focused on the development and commercial...

    Intercept is a biopharmaceutical company focuse...

    Filing Type:    PU
    LogicBio Therapeutics, Inc.

    LogicBio Therapeutics, Inc.

    LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...

    LogicBio is a Cambridge, MA-based genome editin...

    Filing Type:    PU
    Aevi Genomic Medicine, Inc.

    Aevi Genomic Medicine, Inc.

    Aevi Genomic Medicine is focused on translating genetic discoveries into novel the...

    Aevi Genomic Medicine is focused on translating...

    Filing Type:    PU
    Nuvectra Corporation

    Nuvectra Corporation

    NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...

    NuvectraÂŽ is a neurostimulation company commit...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    Cue Biopharma, Inc.

    Cue Biopharma, Inc.

    Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...

    Cue Biopharma is an innovative clinical stage i...

    Filing Type:    PU
    Avalon GloboCare Corp.

    Avalon GloboCare Corp.

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...

    Filing Type:    PU
    Athenex, Inc.

    Athenex, Inc.

    Athenex is a global oncology focused biopharmaceutical company dedicated to the di...

    Athenex is a global oncology focused biopharmac...

    Filing Type:    PU
    Unum Therapeutics Inc.

    Unum Therapeutics Inc.

    Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...

    Unum Therapeutics is a clinical-stage biopharma...

    Filing Type:    PU
    Cyclacel Pharmaceuticals, Inc.

    Cyclacel Pharmaceuticals, Inc.

    Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...

    Cyclacel's founding scientist, Professor Sir Da...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.